The phrase "stem cells" can still bring a shudder to some investors, wisely shy about the riotous debate the field of research sparked last year between fervent camps of various persuasions some concerned more with religious and ethical matters than the advance of biotechnology. (BioWorld Financial Watch)

Private biotech companies planning to go public played the waiting game in 2001. They waited for the right moment, when the window would fly up and investors would flock to their brokers. But just as that window started to inch open late last year, it immediately slammed shut again upon news of accounting scandals and clinical blowups. (BioWorld Financial Watch)

NEW YORK - The nitty-gritty of strategy, partnering and navigating the FDA were among topics covered during the fourth annual BIO CEO & Investor Conference last week, where about 1,500 registrants crowded the meeting rooms of the Waldorf-Astoria Hotel to hear some of the industry's leaders talk about what worked for them, and what didn't. (BioWorld Financial Watch)